Wei-Dong Jia, ShuKui Qin, Jian Zhou, Hui-Chuan Sun, Cheng Huang, Yan Zhiping, Tao Peng, Xuetao Shi, Shanzhi Gu, Li Peng, Yong Zha, Jinfang Zheng, Hong Ren, Kecan Lin, Zhiyu Chen, Ruibao Liu, Zhonghua Liu, Junqin Yang, Qiang Yang, Jia Fan. "Camrelizumab (C) plus rivoceranib (R) with transarterial chemoembolization (TACE) vs TACE alone in unresectable hepatocellular carcinoma (uHCC): A randomized, phase 3 trial.." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.16_suppl.4001